Building on this established collaboration, the new agreement expands the partnership into antibody license, further strengthening the strategic relationship between the two companies.

- Mini oral presentation to highlight initial Phase 1 data of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, in patients with advanced or metastatic solid tumors - Oral ...

The Chinese regulatory agency also cleared the study. About AI-081 AI-081 is a PD-1 and VEGF bispecific antibody with best-in-class potential for the treatment of advanced solid tumors.

A recent article in Frontiers of Immunology, by Dr. Kaissar Tabynov and others, have engineered antibodies to recognize and attack a specific pollen, known as mugwort pollen. Mugwort is a common ...

I-Mab acquires Bridge Health, gaining upstream rights to CLDN18.2 antibody, reducing milestone payments for givastomig and eliminating royalties.

I-Mab has solidif | I-Mab has solidified its pivot to givastomig by buying out the owner of an antibody used in the therapy.

A specially engineered antibody that can accurately deliver RNA treatments into hard-to-reach and hard-to-treat tumors significantly improved survival and reduced tumor sizes in animal models ...

Seemingly harmless SVGs are packed with malicious JavaScript for a phishing redirect to actor-controlled URLs.

A panelist highlights promising early-phase trial data on trispecific antibodies targeting multiple myeloma antigens and CD3, emphasizing their high response rates, manageable safety profiles, and ...